Your browser doesn't support javascript.
loading
Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis.
Lehmann, Lorenz H; Heckmann, Markus B; Bailly, Guillaume; Finke, Daniel; Procureur, Adrien; Power, John R; Stein, Frederic; Bretagne, Marie; Ederhy, Stephane; Fenioux, Charlotte; Hamwy, Omar; Funck-Brentano, Elisa; Romano, Emanuela; Pieroni, Laurence; Münster, Jan P; Allenbach, Yves; Anquetil, Céline; Leonard-Louis, Sarah; Palaskas, Nicolas L; Hayek, Salim S; Katus, Hugo A; Giannitsis, Evangelos; Frey, Norbert; Kaya, Ziya; Moslehi, Javid; Prifti, Edi; Salem, Joe-Elie.
Afiliação
  • Lehmann LH; Department of Cardiology, Angiology, and Pneumology, Heidelberg University Hospital, German Centre for Cardiovascular Research DZHK, Heidelberg, Germany (L.H.L., M.B.H., D.F., F.S., J.P.M., H.A.K., E.G., N.F., Z.K.).
  • Heckmann MB; German Cancer Research Center (DKFZ), Heidelberg, Germany (L.H.L.).
  • Bailly G; Department of Cardiology, Angiology, and Pneumology, Heidelberg University Hospital, German Centre for Cardiovascular Research DZHK, Heidelberg, Germany (L.H.L., M.B.H., D.F., F.S., J.P.M., H.A.K., E.G., N.F., Z.K.).
  • Finke D; Sorbonne Université, Assistance Publique-Hôpitaux de Paris, INSERM, Department of Pharmacology, UNICO-GRECO Cardio-oncology program, Pitié-salpétrière Hospital, Paris, France (G.B., A.P., F.S., M.B., C.F., O.H., J-E.S.).
  • Procureur A; Department of Cardiology, Angiology, and Pneumology, Heidelberg University Hospital, German Centre for Cardiovascular Research DZHK, Heidelberg, Germany (L.H.L., M.B.H., D.F., F.S., J.P.M., H.A.K., E.G., N.F., Z.K.).
  • Power JR; Sorbonne Université, Assistance Publique-Hôpitaux de Paris, INSERM, Department of Pharmacology, UNICO-GRECO Cardio-oncology program, Pitié-salpétrière Hospital, Paris, France (G.B., A.P., F.S., M.B., C.F., O.H., J-E.S.).
  • Stein F; University of California San Diego (J.R.P).
  • Bretagne M; Department of Cardiology, Angiology, and Pneumology, Heidelberg University Hospital, German Centre for Cardiovascular Research DZHK, Heidelberg, Germany (L.H.L., M.B.H., D.F., F.S., J.P.M., H.A.K., E.G., N.F., Z.K.).
  • Ederhy S; Sorbonne Université, Assistance Publique-Hôpitaux de Paris, INSERM, Department of Pharmacology, UNICO-GRECO Cardio-oncology program, Pitié-salpétrière Hospital, Paris, France (G.B., A.P., F.S., M.B., C.F., O.H., J-E.S.).
  • Fenioux C; Sorbonne Université, Assistance Publique-Hôpitaux de Paris, INSERM, Department of Pharmacology, UNICO-GRECO Cardio-oncology program, Pitié-salpétrière Hospital, Paris, France (G.B., A.P., F.S., M.B., C.F., O.H., J-E.S.).
  • Hamwy O; Sorbonne Université, Assistance Publique-Hôpitaux de Paris, INSERM, Department of Cardiology, UNICO-GRECO Cardio-oncology program, Saint-Antoine Hospital, Paris, France (S.E.).
  • Funck-Brentano E; Sorbonne Université, Assistance Publique-Hôpitaux de Paris, INSERM, Department of Pharmacology, UNICO-GRECO Cardio-oncology program, Pitié-salpétrière Hospital, Paris, France (G.B., A.P., F.S., M.B., C.F., O.H., J-E.S.).
  • Romano E; Sorbonne Université, Assistance Publique-Hôpitaux de Paris, INSERM, Department of Pharmacology, UNICO-GRECO Cardio-oncology program, Pitié-salpétrière Hospital, Paris, France (G.B., A.P., F.S., M.B., C.F., O.H., J-E.S.).
  • Pieroni L; Hopital Ambroise-Paré, Neuilly Sur Seine, France (E.F-B.).
  • Münster JP; Center for Cancer Immunotherapy, Department of Oncology, PSL Research University, Institut Curie, Paris, France (E.R.).
  • Allenbach Y; Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Biochimie- Hormonologie, Hôpital Tenon, Paris, France (L.P.).
  • Anquetil C; Department of Cardiology, Angiology, and Pneumology, Heidelberg University Hospital, German Centre for Cardiovascular Research DZHK, Heidelberg, Germany (L.H.L., M.B.H., D.F., F.S., J.P.M., H.A.K., E.G., N.F., Z.K.).
  • Leonard-Louis S; Section of Cardio-Oncology and Immunology, Cardiovascular Research Institute, University of California San Francisco (J.P.M.).
  • Palaskas NL; Department of Internal Medicine (Y.A., C.A.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris, INSERM, Hôpital Pitié-Salpêtrière, France.
  • Hayek SS; Department of Internal Medicine (Y.A., C.A.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris, INSERM, Hôpital Pitié-Salpêtrière, France.
  • Katus HA; Neuropathology (S.L-L.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris, INSERM, Hôpital Pitié-Salpêtrière, France.
  • Giannitsis E; Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston (N.L.P.).
  • Frey N; Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor (S.S.H.).
  • Kaya Z; Department of Cardiology, Angiology, and Pneumology, Heidelberg University Hospital, German Centre for Cardiovascular Research DZHK, Heidelberg, Germany (L.H.L., M.B.H., D.F., F.S., J.P.M., H.A.K., E.G., N.F., Z.K.).
  • Moslehi J; Department of Cardiology, Angiology, and Pneumology, Heidelberg University Hospital, German Centre for Cardiovascular Research DZHK, Heidelberg, Germany (L.H.L., M.B.H., D.F., F.S., J.P.M., H.A.K., E.G., N.F., Z.K.).
  • Prifti E; Department of Cardiology, Angiology, and Pneumology, Heidelberg University Hospital, German Centre for Cardiovascular Research DZHK, Heidelberg, Germany (L.H.L., M.B.H., D.F., F.S., J.P.M., H.A.K., E.G., N.F., Z.K.).
  • Salem JE; Department of Cardiology, Angiology, and Pneumology, Heidelberg University Hospital, German Centre for Cardiovascular Research DZHK, Heidelberg, Germany (L.H.L., M.B.H., D.F., F.S., J.P.M., H.A.K., E.G., N.F., Z.K.).
Circulation ; 148(6): 473-486, 2023 08 08.
Article em En | MEDLINE | ID: mdl-37317858
ABSTRACT

BACKGROUND:

Immune checkpoint inhibitors (ICIs) are approved for multiple cancers but can result in ICI-associated myocarditis, an infrequent but life-threatening condition. Elevations in cardiac biomarkers, specifically troponin-I (cTnI), troponin-T (cTnT), and creatine kinase (CK), are used for diagnosis. However, the association between temporal elevations of these biomarkers with disease trajectory and outcomes has not been established.

METHODS:

We analyzed the diagnostic accuracy and prognostic performances of cTnI, cTnT, and CK in patients with ICI myocarditis (n=60) through 1-year follow-up in 2 cardio-oncology units (APHP Sorbonne, Paris, France and Heidelberg, Germany). A total of 1751 (1 cTnT assay type), 920 (4 cTnI assay types), and 1191 CK sampling time points were available. Major adverse cardiomyotoxic events (MACE) were defined as heart failure, ventricular arrhythmia, atrioventricular or sinus block requiring pacemaker, respiratory muscle failure requiring mechanical ventilation, and sudden cardiac death. Diagnostic performance of cTnI and cTnT was also assessed in an international ICI myocarditis registry.

RESULTS:

Within 72 hours of admission, cTnT, cTnI, and CK were increased compared with upper reference limits (URLs) in 56 of 57 (98%), 37 of 42 ([88%] P=0.03 versus cTnT), and 43 of 57 ([75%] P<0.001 versus cTnT), respectively. This increased rate of positivity for cTnT (93%) versus cTnI ([64%] P<0.001) on admission was confirmed in 87 independent cases from an international registry. In the Franco-German cohort, 24 of 60 (40%) patients developed ≥1 MACE (total, 52; median time to first MACE, 5 [interquartile range, 2-16] days). The highest value of cTnTURL within the first 72 hours of admission performed best in terms of association with MACE within 90 days (area under the curve, 0.84) than CKURL (area under the curve, 0.70). A cTnTURL ≥32 within 72 hours of admission was the best cut-off associated with MACE within 90 days (hazard ratio, 11.1 [95% CI, 3.2-38.0]; P<0.001), after adjustment for age and sex. cTnT was increased in all patients within 72 hours of the first MACE (23 of 23 [100%]), whereas cTnI and CK values were less than the URL in 2 of 19 (11%) and 6 of 22 (27%) of patients (P<0.001), respectively.

CONCLUSIONS:

cTnT is associated with MACE and is sensitive for diagnosis and surveillance in patients with ICI myocarditis. A cTnTURL ratio <32 within 72 hours of diagnosis is associated with a subgroup at low risk for MACE. Potential differences in diagnostic and prognostic performances between cTnT and cTnI as a function of the assays used deserve further evaluation in ICI myocarditis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Miocardite Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Miocardite Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article